QQQ
-7.56
406.32
-1.9%
BTC/USD
-484.79
54236.24
-0.89%
DIA
-8.82
366.85
-2.46%
SPY
-10.05
479.49
-2.14%
TLT
+ 3.71
143.11
+ 2.53%
GLD
-0.24
167.36
-0.14%

Expert Ratings For Sarepta Therapeutics

October 15, 2021 12:16 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Expert Ratings For Sarepta Therapeutics

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company’s business to predict how a stock will trade over the upcoming year.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 0 5 0 0
Last 30D 0 0 1 0 0
1M Ago 1 0 1 0 0
2M Ago 0 0 1 0 0
3M Ago 0 0 2 0 0

In the last 3 months, 6 analysts have offered 12-month price targets for Sarepta Therapeutics. The company has an average price target of $95.33 with a high of $125.00 and a low of $75.00.

Below is a summary of how these 6 analysts rated Sarepta Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

price target chart

This average price target has increased by 5.54% over the past month.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.

Posted-In:

Analyst Ratings

Related Articles

Analyst Ratings For Sarepta Therapeutics

Analyst Ratings For Sarepta Therapeutics

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter: read more
What 5 Analyst Ratings Have To Say About Sarepta Therapeutics

What 5 Analyst Ratings Have To Say About Sarepta Therapeutics

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter: read more
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021

Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021

  read more

JP Morgan Upgrades Sarepta Therapeutics to Overweight, Raises Price Target to $130

JP Morgan analyst Anupam Rama upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Neutral to Overweight and raises the price target from $88 to $130. read more